Spravato is a drug that is used to treat schizophrenia, severe depression, and bipolar disorder. It is a medication that works by blocking dopamine receptors in the brain.
 
Spravato can cause side effects such as weight gain, sleepiness, and drooling.
 
The patient should stop taking Spravato if they experience any of these side effects.
 
Some people who take this drug experience an increase in their appetite, which can lead to weight gain and obesity. This can be a problem for those who are already overweight or obese before they start taking the drug because it may not be possible to lose weight while on Spravato treatment.

People taking Spravato were 51% to 70% less likely to suffer from a major depressive disorder compared to those taking a placebo.
 
If you have depression or relapsing treatment-resistant depression, don’t let your symptoms rule your life. Help may still be available, and it’s worth asking your doctor or therapist about the benefits of Spravato (the brand name for esketamine). Spravato is a prescription drug available at licensed clinics.
 
In a 4-week clinical study, Spravato reduced symptoms of depression in people taking the drug. One group received Spravato and oral antidepressants. The other group received a placebo (treatment with no active substance) and an oral antidepressant. Depressive symptoms are measured on a scale of 0 to 60, with higher scores indicating more severe depressive symptoms.
 
Spravato works differently than other antidepressants. Traditional antidepressants increase levels of naturally occurring brain chemicals such as serotonin, norepinephrine, and dopamine. These chemical messengers also called neurotransmitters, initiate and regulate communication between different cells in the brain. Chemical messengers also help regulate and influence our emotions.

Esketamine may hold promise as a treatment for patients diagnosed with a major depressive disorder whose symptoms have not improved despite various medications and therapies. The drug’s easy intranasal route of administration and rapid onset of action makes it different from many other antidepressants, which can take weeks to take effect.
 
Furthermore, esketamine is only part of the treatment for people with depression. So far, it has only been shown to be effective in combination with oral antidepressants. For these reasons, esketamine is not considered a first-line treatment option for depression. It’s only for people with moderate to severe depression who aren’t getting help from at least two other antidepressants.
 
Esketamine is made from a drug called ketamine, an anesthetic that has been used to treat depression for many years. But only recently has the stronger version of ketamine, esketamine, been approved by the FDA as a nasal spray specifically for people with treatment-resistant depression.
Esketamine is a narcotic.

The active ingredient in Spravato is called esketamine, which is made from ketamine. Ketamine is approved by the U.S. Food and Drug Administration (FDA) as an anesthetic. Ketamine is listed as a drug in the Narcotics Control Regulations under the Controlled Drugs and Substances Act and should be adjudicated by the Provincial Narcotics Monitoring System (NMS) 20.

You can receive esketamine through specific clinics and licensed physicians that have the ability to prescribe esketamine through a treatment program that is used to help with depression. This includes Psychiatry Unplugged. Our licensed and top psychiatrists at Psychiatry Unplugged are able to provide this very specific medication to patients who are on a trusted and approved treatment plan. If you are interested in how esketamine can help you, contact our clinic today to learn more about the programs we offer, and how in conjunction with this medical prescription, you may begin to feel more like yourself once more. For more information and details, please contact us or book an appointment online. We are located at 121 W. Lexington Dr. Ste 414 Glendale, CA 91203.We serve patients from Glendale CA, Hollywood CA, Calabasas CA, Burbank CA, Studio City CA, and Pasadena CA.